Cephalon Rejects Acquisition Bid from Valeant

By Bizclik Editor

Written BY: Kristin Craik

Pennsylvania-based Cephalon formally rejected Ontario-based Valeant Pharmaceuticals acquisition bid yesterday. Valeant intends to go around the Cephalon Board of Directors to contact the company’s stockholders with proposed offer.

The Cephalon Board of Directors claims Valeant’s bid is inadequate and not in shareholders’ best interests. Specifically, the Valeant’s proposed offer significantly undervalues Cephalon’s worth, especially with its diversified portfolio of marketed and pipeline products. The wording of the bid was also called into question by the Board especially in the use that Valeants bid comes from a “worst-case scenario.”

Kevin Buchi, Cephalon's Chief Executive Officer, said in a statment, "This is all about shareholder value. The Cephalon Board of Directors is committed to maximizing value for our shareholders, and we take this responsibility very seriously."

Valeant’s bid also stated that they intended to replace all Cephalon’s directors with Valeant nominees.

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

Click here to read the latest edition of Business Review Canada

Valeant hopes to continue with this acquisition. Valeant believes that if a due diligence investigation was allowed, an increase of offer price in the bid would result. Valeant says they are committed to enabling Cephalon stockholders the ability to make an informed decision on offer acceptance.

J. Michael Pearson, Valeant's Chairman and CEO said "In the three weeks since our initial offer, Valeant has recruited seven experienced candidates to serve as director-nominees of Cephalon. We have arranged financing for our proposed acquisition of Cephalon. We have received positive feedback from many of the largest stockholders of Cephalon. We stand ready to quickly commence and close our transaction as proposed, unless Cephalon stockholders do not support our offer, in which case we will focus our attention on other opportunities to invest our capital. While we are disappointed with the response from Cephalon's board, we remain committed to our process, which includes trying to find a modest amount of additional value if Cephalon engages with us and allows us to conduct due diligence, which we believe would take only 2-3 weeks."

Following SEC approval of consent solicitation, Valeant plans to take a consent statement available to Cephalon stockholders for further consideration.

Share

Featured Articles

Broadridge study reveals huge impact of AI on C-suite

Broadridge Financial Solutions spoke to 500 C-suite executives from across the globe, many of whom said AI was significantly changing the way they work

PwC's Kathryn Kaminsky – the role of boards on social issues

As Vice Chair Trust Solutions Co-Leader at PwC, Kathryn Kaminsky says boards play an important role in helping businesses take action on social issues

Why your business needs a Chief Transformation Officer

Responsible for driving growth and change, the Chief Transformation Officer is the latest addition to the C-suite as business undergoes major change

12 top AI and ML trends for the enterprise in 2023 – Dataiku

Technology & AI

From NYC to Hong Kong, the rise of the private members' club

Leadership & Strategy

Meet the CEO: Jill Stelfox of Panzura, exclusive interview

Leadership & Strategy